EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

PD ‐1/ PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level

Zixian Jin iD, Jiping Wang, Jiajing Sun, Chengchu Zhu, Jian Zhang, Bo Zhang

Cancer Reports · 2023

DOI: 10.1002/cnr2.1794 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Reports, 2023. Verfasst von Zixian Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang P…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunochemotherapy has become a new treatment for advanced esophageal squamous cell carcinoma (ESCC).

Aims

We aimed to study the clinical efficacy and toxicity of immunochemotherapy based on PD‐1/PD‐L1 compared with chemotherapy alone in the treatment of advanced ESCC, focusing on analyzing the influence of PD‐L1 expression level. Methods and Results Five randomized controlled trials comparing PD‐1/PD‐L1 based immunochemotherapy with chemotherapy alone for advanced ESCC were included. We extracted efficacy data (objective response rate [ORR], disease control rate [DCR], overall survival [OS] rate, progression‐free survival [PFS] rate) and safety data (treatment‐related adverse events, treatment‐related mortality) and performed meta‐analyses. Compared with chemotherapy alone, the ORR and DCR of immunochemotherapy increased by 2.05 times and 1.54 times, respectively. Overall, patients receiving immunochemotherapy had a significant long‐term survival advantage (OS: hazard ratio [HR] = 0.68, 95% confidence intervals [CI] 0.61–0.75; PFS: HR = 0.62, 95% CI 0.55, 0.70, respectively). Even with PD‐L1 tumor proportion score

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansProgrammed Cell Death 1 ReceptorB7-H1 AntigenTreatment Outcome

Stichwörter der Autor:innen

ESCCPD-1PD-L1immunochemotherapysurvival

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 Antigen

Autor:innen und Institutionen

  • Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, China.
  • Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, China.
  • Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Zhejiang University, Linhai, China.

ORCID-Profile: Zixian Jin

Zitieren

APA

Jin, Z., Wang, J., Sun, J., Zhu, C., Zhang, J., & Zhang, B. (2023). PD ‐1/ PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level. Cancer Reports. https://doi.org/10.1002/cnr2.1794

Vancouver

Jin Z, Wang J, Sun J, Zhu C, Zhang J, Zhang B. PD ‐1/ PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level. Cancer Reports. 2023. doi:10.1002/cnr2.1794

BibTeX
@article{Jin2023,
  author = {Jin, Zixian and Wang, Jiping and Sun, Jiajing and Zhu, Chengchu and Zhang, Jian and Zhang, Bo},
  title = {PD ‐1/ PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level},
  journal = {Cancer Reports},
  year = {2023},
  doi = {10.1002/cnr2.1794}
}
Kostenlos starten →